BioSpace News Archive

Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer, will present a company overview at two upcoming investor conferences in March.

AIDS Healthcare Foundation welcomed a letter signed by 46 Members of the U.S. House of Representatives asking the Trump Administration to make a potential vaccine against the coronavirus disease accessible, affordable and available..

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the Cowen and Company 40th Annual Health Care Conference on Tuesday, March 3, 2020

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2019.

Amedisys, Inc. (NASDAQ: AMED), one of America’s leading home health, hospice and personal care companies, today announced that Paul B. Kusserow, President and Chief Executive Officer, will present at the Raymond James 41st Annual Institutional Investors Conference in Orlando, Florida on Tuesday, March 3, 2020.

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported fourth quarter and year-end 2019 financial results and provided a corporate update.

Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas anticipated to complete enrollment in first quarter of 2021

Reported Full Year 2019 Global Net Product Revenues of $42 Million and Fourth Quarter 2019 Global Net Product Revenues of $14 Million

Amarin Corporation plc, announced financial results for the quarter and year ended December 31, 2019 and provided an update on company operations.

Stilla Technologies, a leading provider of pioneering digital PCR (dPCR) solutions for high-precision genetic analyses, just announced it will be joining an initiative led by Yuzi Holdings and TusPark Science & Technology Service Group (TusPark) to donate two Naica Systems to City of Zhengzhou and City of Xinyang², in China, to help them better detect the coronavirus and monitor its mutations.